http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
-
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
-
F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021
-
F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021
-
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
-
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
-
F-star Therapeutics to Present at Upcoming Investor Conferences
-
F-star Therapeutics to Present at Upcoming Investor Conferences
-
F-Star Therapeutics (FSTX) Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
-
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
-
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
-
F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021
-
F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021
-
Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
-
Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
-
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
-
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
-
F-Star Therapeutics Inc. (FSTX) Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
-
F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
-
F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
-
F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
-
F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update
-
F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021
-
F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021
-
F-star Therapeutics to Present at Upcoming Investor Conferences
-
F-star Therapeutics to Present at Upcoming Investor Conferences

